Clinical trial
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
NCT00195260 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00195260 |
|---|---|
| Title | Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors |
| Official title | Phase I Dose-Escalation Study Of Oral SKI-606 In Subjects With Advanced Malignant Solid Tumors |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | bosutinib |
| Enrollment | 151 |
| Start date | Oct 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: